Accelerating Medicines Partnership® SCHIZOPHRENIA
Participating in the Study
Participating in the Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) research study will allow scientists to understand better what happens to young people at clinical high risk for psychosis. By knowing more, scientists can improve mental health interventions and the support provided to young people.

For Clinicians


Many young people who are experiencing new or worsening mental health symptoms first go to their primary care provider for help. Young people experiencing signs of clinical high risk for psychosis may have difficulty describing their symptoms, or their symptoms may sound vague or confusing. Signs that someone may be at clinical high risk for psychosis may include: difficulty thinking or concentrating; changes in thought content such as suspiciousness, odd thoughts, or unusual beliefs; perceptual disturbances such as hearing or seeing things others do not, or increased sensitivity to sights and sounds; decreased motivation or withdrawing from friends and family; and new problems at work or school. People who show these signs may be at increased risk for developing schizophrenia or a related disorder later.

If you are a clinician or someone who knows a young person experiencing these symptoms, we hope you will share this information with them and consider inviting them to participate in the study at one of our participating study sites. Participating in this research study will allow scientists to understand better what happens to young people at clinical high risk for psychosis. By knowing more, scientists can improve mental health interventions and the support provided to young people.


Last Reviewed on May 2, 2022